Articles On Alchemia (ASX:ACL)

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday trade. WINNERS Scrol...

There are many reasons why a company might change its name, from being taken over to hiding a shady past. This year 114 companies have changed their name. Family cyber security provider Wangle Technologies became the much more fitting Famil...

Once biotechnology company Alchemia has acquired hemp grower Australian Primary Hemp (ASX: APH) as part of a shift into hemp production and distribution. To complete its reverse takeover (RTO) listing, the company raised $5.7 million by iss...

Imugene Limited (ASX: IMU), an Australian-headquartered clinical-stage immuno-oncology company, focusses on the development of emerging immunotherapies to enhance the efficacy of cancer treatments. The company utilises its unique platform t...

The ASX’s 32 tradeable pot stocks and pot stock wannabees are down 17 per cent over the last 12 months. The Small Ords (ASX:XSO) has risen 1.62 per cent in the same time, and the All Ords (ASX:XAO) and the ASX200 (ASX:XJO) are both up over...

Vigilance and self-awareness on the performance of stocks is perhaps the most effective catalyst that drives one on the path to become a successful investor/trader. Potential shortfalls, sudden surges, certain market anomalies, adverse econ...

It has been a few lean years at Alchemia (ASX: ACL). In October 2014 the Phase III trial of an anti-cancer drug failed and its shares plummeted. As often happens with failed biotechs, the next several months (and years) were spent looking f...